Responses

Download PDFPDF
23-gauge versus 20-gauge system for pars plana vitrectomy: a prospective randomised clinical trial
Compose Response

Plain text

  • No HTML tags allowed.
  • Web page addresses and e-mail addresses turn into links automatically.
  • Lines and paragraphs break automatically.
Author Information
First or given name, e.g. 'Peter'.
Your last, or family, name, e.g. 'MacMoody'.
Your email address, e.g. higgs-boson@gmail.com
Your role and/or occupation, e.g. 'Orthopedic Surgeon'.
Your organization or institution (if applicable), e.g. 'Royal Free Hospital'.
Statement of Competing Interests

PLEASE NOTE:

  • A rapid response is a moderated but not peer reviewed online response to a published article in a BMJ journal; it will not receive a DOI and will not be indexed unless it is also republished as a Letter, Correspondence or as other content. Find out more about rapid responses.
  • We intend to post all responses which are approved by the Editor, within 14 days (BMJ Journals) or 24 hours (The BMJ), however timeframes cannot be guaranteed. Responses must comply with our requirements and should contribute substantially to the topic, but it is at our absolute discretion whether we publish a response, and we reserve the right to edit or remove responses before and after publication and also republish some or all in other BMJ publications, including third party local editions in other countries and languages
  • Our requirements are stated in our rapid response terms and conditions and must be read. These include ensuring that: i) you do not include any illustrative content including tables and graphs, ii) you do not include any information that includes specifics about any patients,iii) you do not include any original data, unless it has already been published in a peer reviewed journal and you have included a reference, iv) your response is lawful, not defamatory, original and accurate, v) you declare any competing interests, vi) you understand that your name and other personal details set out in our rapid response terms and conditions will be published with any responses we publish and vii) you understand that once a response is published, we may continue to publish your response and/or edit or remove it in the future.
  • By submitting this rapid response you are agreeing to our terms and conditions for rapid responses and understand that your personal data will be processed in accordance with those terms and our privacy notice.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.

Vertical Tabs

Other responses

Jump to comment:

  • Published on:
    Authors' Response
    • Susanne Binder, Professor and Head of the Department of Ophthalmology
    • Other Contributors:
      • Barbara Wimpissinger, Lukas Kellner, Werner Brannath, Katharina Krepler, Ulrike Stolba, Christian Mihalics.

    Dear editor,

    We would like to give a response to the letter of Dr. Anshuman Sinha concerning our article "23 Gauge versus 20 Gauge System for Pars Plana Vitrectomy: A Prospective Randomized Clinical Trial".

    For analysis of postoperative pain we used a simplified verbal rating scale (ranging from 0, meaning no pain, to 3, meaning severe pain). The standardized verbal rating scale reaches from 0 (no pain) to...

    Show More
    Conflict of Interest:
    None declared.
  • Published on:
    Comments on 23-gauge versus 20-gauge system for pars plana vitrectomy
    • Anshuman Sinha, Fellow - Retina & Vitreous
    • Other Contributors:
      • Ritesh Narula, Raja Narayanan

    Dear editor,

    We read with interest the paper by Wimpissinger et al comparing sutureless 23-gauge system to a standard 20-gauge system for pars plana vitrectomy, in a randomized clinical trial.[1] We aim to highlight a few issues in the design, methodology and analysis.

    The authors have analysed postoperative pain and conjunctival injection as primary outcome measures. The effort by the assessor to elicit a...

    Show More
    Conflict of Interest:
    None declared.